A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors


Study Number
569719
Phase
1
Age Group
Adult
Purpose

The purpose of this study is to assess the safety and tolerability of ASP9801 and to determine the recommended phase 2 dose (RP2D). The study will also evaluate antitumor activity, objective response rate, pharmacokinetics and virus shedding of ASP9801.

Full Title

9801-CL-0101 A Phase 1, Open-label Study of ASP9801, an Oncolytic Virus, Administered by Intratumoral Injection in Patients with Advanced/Metastatic Solid Tumors

ClinicalTrials.Gov ID
NCT03954067

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.